



25 China.

26 <sup>10</sup> BGI-ShenZhen, Shenzhen 518103, China.

27 <sup>11</sup> Shenzhen Bay Laboratory, Shenzhen 518000, China.

28 <sup>12</sup> Guangdong Provincial Key Laboratory of Genome Read and Write, Shenzhen 518120, China

29 <sup>13</sup> Department of Haematology, Wellcome-Medical Research Council Cambridge Stem Cell

30 Institute, University of Cambridge, Cambridge, CB2 0AW, UK

31 <sup>14</sup> Lead Contact

32 # These authors contributed equally to this work

33 \* Corresponding authors

34 **Feng Liu**, liuf@ioz.ac.cn; **Cheng Li**, cheng\_li@pku.edu.cn

35 **ABSTRACT**

36 Limited knowledge of underlying cellular and molecular mechanisms of hematopoietic stem  
37 cell and multipotent progenitor (HSC/MPP) expansion within their native niche has impeded  
38 the application of stem-cell based therapies for hematological malignances. Here, we  
39 constructed a spatiotemporal transcriptome map of mouse fetal liver (FL) as a platform for  
40 hypothesis generation and subsequent experimental validation of novel regulatory mechanisms.  
41 Single-cell transcriptomics revealed three transcriptionally heterogeneous HSC/MPP subsets,  
42 in which CD93-enriched subset exhibited enhanced stem cell properties. Moreover, by  
43 employing the integrative analysis of single-cell and spatial transcriptomics, we identified novel  
44 HSC/MPP ‘pocket-like’ units (HSC PLUS), composed of niche cells (hepatoblasts, stromal  
45 cells, endothelial cells, and macrophages), and enriched with growth factors. Unexpectedly,  
46 macrophages showed a 11-fold enrichment in the HSC PLUS. Functionally, macrophage-  
47 HSC/MPP co-culture assay and small molecule screening, respectively, validated the  
48 supportive role of macrophages and growth factors (MDK, PTN, and IGFBP5) in HSC/MPP  
49 expansion. Finally, cross-species analysis and functional validation showed conserved cell-cell  
50 interactions and expansion mechanisms but divergent transcriptome signatures between mouse  
51 and human FL HSCs/MPPs. Taken together, these results provide an essential resource for  
52 HSC/MPP development in FL, with implications for functional HSC/MPP expansion *ex vivo*.

53

54 **INTRODUCTION**

55 In mammals, hematopoietic stem cells and multipotent progenitors (HSCs/MPPs), occupying  
56 the top of hematopoietic hierarchy, display multilineage differentiation and self-renewal  
57 abilities<sup>1</sup>. Studying HSC/MPP expansion holds great promise for regenerative medicine<sup>2</sup>, and  
58 significant efforts have been devoted to fulfilling long-term *ex vivo* HSC/MPP expansion via  
59 genetic manipulation or optimization of culture conditions<sup>3,4</sup>. Nevertheless, in current *ex vivo*  
60 HSC/MPP expansion culture, the key challenge is how to maintain the stem cell properties;  
61 therefore, a comprehensive understanding of HSC/MPP expansion within their native niche *in*  
62 *vivo* is required.

63 Highly vascularized fetal liver (FL) serves as the transitory developmental site for various  
64 sources of hematopoietic cells (HCs). In mice, the early wave of HCs colonizing the FL contains  
65 yolk sac erythro-myeloid progenitors (EMP), which will generate erythroid-myeloid lineages,  
66 including macrophages<sup>5,6</sup>. Subsequently, aorta-gonad-mesonephros (AGM)-derived HSCs  
67 migrate into the FL for maturation, expansion, and differentiation<sup>7-9</sup>. Mounting evidence in mice  
68 demonstrates that FL structural niche cells, including endothelial cells (ECs), stromal cells, and  
69 hepatoblasts, interact with HSCs/MPPs via diverse growth factors, cytokines, and  
70 chemokines<sup>10-13</sup>. These aforementioned findings preferentially focus on the effects of certain  
71 niche cell types or specific signaling molecules on HSC/MPP expansion. However, the  
72 mechanisms underlying the complex interplay among HSCs/MPPs and distinct niche cells, and  
73 the systematic regulatory network for HSC/MPP expansion remain elusive.

74 Single-cell RNA sequencing (scRNA-seq) represents a powerful tool to map cell atlas of  
75 single organ or multiple organs<sup>14,15</sup>. However, the weakness of scRNA-seq is the loss of

76 information about the cell-type spatial organization within intact organs. To expand our  
77 understanding of the spatial organization of diverse cell types in an unbiased manner, spatial  
78 transcriptomics (ST) has been developed<sup>16</sup>. Here, to examine the organ-wide regulatory  
79 mechanisms of HSC/MPP expansion, we employed scRNA-seq and ST (including 10x Visium  
80 and Stereo-seq) to generate a spatiotemporal transcriptome map of mouse FL. With this map,  
81 we revealed the transcriptional heterogeneity of HSCs/MPPs, with a focus on a CD93<sup>+</sup> subset  
82 exhibiting enhanced stem cell properties. We also decoded the architectural and molecular bases  
83 of HSC/MPP expansion. Furthermore, cross-species comparative analysis identified both  
84 conserved and divergent cellular and molecular events between mouse and human FL  
85 hematopoiesis. The map is accessible through an intuitive and interactive web portal at  
86 [http://liulab.ioz.ac.cn/fetal\\_liver/](http://liulab.ioz.ac.cn/fetal_liver/). Together, our study reports a spatiotemporal transcriptomics  
87 blueprint for understanding HSC/MPP development in FL and provides valuable insights into  
88 HSC/MPP expansion *ex vivo*.

89

## 90 RESULTS

### 91 Single-cell transcriptomics atlas of the developing mouse FL

92 Previous studies have shown that FL-colonized HSCs/MPPs acquire definitive signatures from  
93 E11.5 to E12.5<sup>17</sup>, followed by exhibiting expansion and differentiation characteristics from  
94 E12.5 to E14.5<sup>7,18</sup>. To resolve the temporal dynamics of HSCs/MPPs and their niche at the  
95 transcriptomics level, we employed 10x Genomics to generate a single-cell resolution cell atlas  
96 of the developing FL at one-day intervals between E11.5 and E14.5 (Fig. 1a). To enrich HCs  
97 and ECs, we used fluorescence-activated cell sorting (FACS) at these time points to separately  
98 sort HCs, ECs, and non-hematopoietic/non-endothelial cells from the FL, and subsequently  
99 pooled them together in certain ratios for sequencing (see MATERIALS AND METHODS;  
100 Supplementary information, Fig. S1a, b). In total, 32,449 single cells were retained for Uniform  
101 Manifold Approximation and Projection (UMAP)<sup>19</sup> analysis after quality control (Fig. 1b;  
102 Supplementary information, Fig. S1c, d). Based on the signature gene expression, we annotated  
103 21 cell clusters (Fig. 1c; Supplementary information, Fig. S1e, f and Table S1), including 18  
104 HC clusters and three structural niche cell clusters, and found that their fractions were  
105 dynamically correlated with the developmental stages (Supplementary information, Fig. S1g).  
106 Specifically, HSCs/MPPs [cluster (C) 1, C2, and C3] exhibited high expression levels of stem  
107 cell signature genes *Mycn*, *Hlf*, and *Mecom*<sup>20,21</sup>. Lymphoid progenitors (C4) were marked by  
108 *Ccr9*, *Il7r*, and *Flt3*. Myeloid progenitors (C6) were characterized by the expression of *Mpo*,  
109 *Spi1*, and *Ccl9*<sup>22</sup>. Three structural niche cell clusters consisted of C19 ECs (*Lyve1*, *Kdr*, and  
110 *Pecam1*), C20 stromal cells (*Pdgfra*, *Alcam*, and *Ncam1*), and C21 hepatoblasts (*Afp*, *Alb*, and  
111 *Ttr*) (Fig. 1c; Supplementary information, Fig. S1f).

112 The development of HSCs/MPPs and FL structural niche cells is tightly regulated by  
113 dynamic transcriptional programs<sup>13,17</sup>. Accordingly, we focused on the transcriptional dynamics  
114 of HSCs/MPPs and structural niche cells. Analysis of differentially expressed genes (DEGs)  
115 was performed among four stages, and gene ontology (GO) analysis of DEGs in HSCs/MPPs  
116 identified that lymphoid program and immune response were enriched at E11.5 and E12.5, and  
117 hematopoietic development and mitotic cell cycle regulation were enriched at E13.5 and E14.5  
118 (Fig. 1d, e). This suggests that the transcriptional dynamics of HSCs/MPPs in the developing  
119 FL underlies the maturation and expansion of HSCs/MPPs, which is consistent with previous  
120 reports<sup>17,23</sup>. Moreover, GO analysis showed that mitotic cell cycle regulation and cell growth  
121 were also enriched in different types of structural niche cells, indicating a global increase in  
122 cell number and size to accommodate the FL expansion. Specifically, ECs exhibited vasculature  
123 sprouting at E11.5 and E12.5, and cell-cell adherent junctions at E13.5 and E14.5  
124 (Supplementary information, Fig. S2a, b), representing a gradual formation of the FL  
125 vasculature. For the stromal cells, ribonucleoprotein biogenesis and RNA translation were  
126 enriched at E11.5 and E12.5, and extracellular structure organization and growth factor  
127 production were enriched at E13.5 and E14.5 (Supplementary information, Fig. S2c, d),  
128 suggesting that stromal cells provide structural support and signaling interaction for tissue  
129 development. GO analysis of hepatoblasts showed that ribosome biogenesis was enriched at  
130 E11.5 and E12.5, and metabolic regulation was enriched at E13.5 and E14.5 (Supplementary  
131 information, Fig. S2e, f). Taken together, we generated the first fully-annotated single-cell  
132 resolution atlas of mouse FL, shown in a freely-available website (Supplementary information,  
133 Video S1), to gain a comprehensive understanding of cellular composition dynamics, cell type-

134 specific gene expression and stage-specific biological functions of both HSCs/MPPs and  
135 structural niche cells during FL development.

136

### 137 **CD93-enriched HSCs/MPPs exhibit enhanced stem cell properties**

138 To further dissect the transcriptome features of HSCs/MPPs, we focused on HSC/MPP1-3  
139 clusters and explored the underlying differences among them. GO and DEG analyses indicated  
140 enrichment of hematopoietic regulation and differentiation, active translation processes, and  
141 cell cycle regulation in HSC/MPP1-3, respectively (Fig. 2a, b). In HSC/MPP1, the expression  
142 of *Mycn*, *Mecom*, and *Hlf* was enriched; in HSC/MPP2, metabolic and lineage-specific genes  
143 were highly expressed; and in HSC/MPP3, cell cycle related genes showed highly enriched  
144 expression (Fig. 2b, c). To further evaluate the stem cell properties of heterogeneous  
145 HSCs/MPPs, we calculated hscScore as previously reported<sup>24</sup>, and found that the highest score  
146 was seen in HSC/MPP1 (Fig. 2d; Supplementary information, Table S2); meanwhile, trajectory  
147 analysis<sup>25</sup> among HSC/MPP subsets and downstream myeloid and lymphoid progenitors  
148 revealed that HSC/MPP1 occupied the top of hematopoietic hierarchy (Fig. 2e). Overall, these  
149 results indicate that HSC/MPP1 exhibit the most robust stem cell transcriptome feature,  
150 compared to HSC/MPP2-3.

151 To enrich HSC/MPP1 cells, we identified a cell-surface marker gene, *Cd93*, the expression  
152 of which was upregulated in HSC/MPP1 relative to HSC/MPP2-3 (Fig. 2f). Given that *Cd93*  
153 (also known as *AA4.1*) has been shown to be expressed in hematopoietic progenitors<sup>26-28</sup>, we  
154 asked whether the combination of CD93 and other HSC/MPP markers, such as Lineage<sup>-</sup> Sca-  
155 1<sup>+</sup>c-Kit<sup>+</sup> (LSK), Flt3<sup>-</sup>LSK, and CD150<sup>+</sup>CD48<sup>-</sup>LSK (SLAM-LSK)<sup>29,30</sup>, can further purify

156 HSCs/MPPs with robust stem cell properties. Flow cytometry analysis indicated that LSK  
157 (Supplementary information, Fig. S3a), SLAM-LSK (Supplementary information, Fig. S3c),  
158 and Flt3<sup>-</sup>LSK (Supplementary information, Fig. S3e) cells at E14.5 could be clearly divided  
159 into CD93<sup>+</sup> and CD93<sup>-</sup> groups. Colony-forming unit (CFU) analysis showed that CD93<sup>+</sup> cells  
160 (CD93<sup>+</sup>LSK, CD93<sup>+</sup>Flt3<sup>-</sup>LSK, and CD93<sup>+</sup>SLAM-LSK) exhibited a higher colony-forming  
161 ability than CD93<sup>-</sup> cells (Supplementary information, Fig. S3b, d, f). Among them,  
162 CD93<sup>+</sup>SLAM-LSK cells displayed the most robust colony-forming ability of CFU-granulocyte,  
163 erythroid, macrophage, and megakaryocyte (CFU-GEMM) than other HSC/MPP groups  
164 (Supplementary information, Fig. S3d). To evaluate the engraftment ability of HSCs/MPPs  
165 purified by CD93<sup>+</sup>SLAM-LSK combination, we performed primary and secondary  
166 transplantation assays. The results showed that E14.5 CD93<sup>+</sup>SLAM-LSK cells exhibited higher  
167 reconstitution and self-renewal abilities than CD93<sup>-</sup> SLAM-LSK cells (Fig. 2g-j). Moreover, to  
168 determine whether the CD93 can enrich HSCs/MPPs from heterogeneous LSK cells<sup>31,32</sup>, we  
169 performed primary transplantation assay and the results showed that E14.5 CD93<sup>+</sup>LSK cells  
170 exhibited a higher short-term (8 weeks) and long-term (16 weeks) reconstitution abilities than  
171 LSK cells (Supplementary information, Fig. S3g); meanwhile, we also found that both E14.5  
172 CD93<sup>High</sup>- and CD93<sup>Mid</sup> LSK cells exhibited higher colony-forming and short-term (4 weeks)  
173 reconstitution abilities than the CD93<sup>Low</sup> LSK cells (Supplementary information, Fig. S3h, i).  
174 Furthermore, to reveal the functional role of CD93 in FL HSC/MPP development, we  
175 characterized the E14.5 FL HSC/MPP phenotype of CD93 genetic mutants (CD93 KO), whose  
176 knockout efficiency was validated at protein level (Supplementary information, Fig. S4a).  
177 Consequently, although the absolute number of whole FL cells and the proportion of

178 undifferentiated Lineage<sup>-</sup> cells had no obvious change in the CD93 KO embryos  
179 (Supplementary information, Fig. S4b, c), the proportion of HSCs/MPPs (LSK cells and  
180 SLAM-LSK cells) was decreased in the CD93 KO embryos (Supplementary information, Fig.  
181 S4d-f). Taken together, CD93 is not only a surface marker for characterizing HSC/MPP  
182 heterogeneity, but also functionally required for FL HSC/MPP development.

183

184 **Integration of scRNA-seq and ST decodes cell-cell interactions between HSCs/MPPs and**  
185 **niche cells**

186 During embryogenesis, the FL provides a supportive niche for HSC/MPP development,  
187 however, the manner by which HSCs interact dynamically with their niche components remains  
188 elusive. To this end, we used CellPhoneDB<sup>33,34</sup> to construct an unbiased HSC/MPP-niche cell  
189 interaction network, with a focus on structural niche cells and macrophages (Fig. 3a), the latter  
190 of which have been shown to act as a niche component for HSC/MPP development in the FL  
191 equivalent of zebrafish<sup>35</sup> and mouse AGM region<sup>36</sup>. In-depth analysis identified several well-  
192 known ligand–receptor interactions involved in HSC/MPP development, such as  
193 TGFB1–TGFBR1, TEK–ANGPT1, and IGF2–IGF1R<sup>37-39</sup>. Importantly, we identified several  
194 previously unrecognized ligand–receptor interactions (Fig. 3b, c), including those related to cell  
195 growth (FLT1–VEGFB, HGF–CD44, MDK–LPR1, IGF1–IGF1R, and PTN–PTPRS)<sup>40-43</sup>,  
196 cytokine (CCL3–IDE and CCL4–SLC7A1)<sup>44</sup>, and Notch signaling (DLK1–NOTCH3 and  
197 DLK–NOTCH4)<sup>45</sup>.

198 To determine whether the predicted signaling interactions indeed exist among the  
199 anatomically-organized cells, we performed 10x Visium ST using four slices from an E14.5

200 embryo along the dorsal-ventral axis, with a focus on the FL region (Fig. 3d-f). We also assessed  
201 the performance of ST using region specific markers, such as lung and intestine regions  
202 (Supplementary information, Fig. S5a). The joint dataset of FL region consisted of 3,791  
203 individual spots after filtering (Supplementary information, Fig. S5b, c). To show the spatial  
204 organization of principal cell types in an unbiased manner, we performed deconvolution  
205 analysis<sup>46,47</sup> by assigning an enrichment score for each spot with cell type signature genes  
206 derived from scRNA-seq. After deconvolution, two spot patterns (first pattern and second  
207 pattern) were shown based on the enrichment score of top two cell types, and then mapped to  
208 the original FL region (Fig. 3g, h). As expected, erythroid cells and hepatoblasts showed the  
209 highest enrichment score in most spots, indicating that they are the predominated cell  
210 components of FL. To specifically determine the spatial organization of HSCs/MPPs and their  
211 interactive niche cells (ECs, stromal cells, hepatoblasts and macrophages), we regarded the  
212 spots as credible for one cell type, according to that the enrichment score of those cell types is  
213 higher than a threshold (80% to HSCs/MPPs and 70% to niche cells), and then mapped them  
214 to the original FL region (Supplementary information, Fig. S6a). To evaluate the performance  
215 of ST in resolving spatial organization, we examined the expression of cell type-specific genes  
216 in the candidate spots. As expected, *Hlf* and *Mecom* were selectively enriched in the HSC/MPP-  
217 localized spots (Supplementary information, Fig. S6b); *Ly86* and *Cd68* were specifically  
218 expressed in the macrophage-localized spots (Supplementary information, Fig. S6g); and the  
219 similar results were also observed in the structural niche cells-localized spots (Supplementary  
220 information, Fig. S6c-f). Taken together, ST profiles the spatial organization of FL for further  
221 decoding cell-cell interactions predicted by scRNA-seq (see below).

222

223 **Identification of expansion units of HSCs/MPPs**

224 To determine the architectural basis of cell-cell interactions, we defined HSC/MPP-localized  
225 spots as intra-spots (indicating the closest relationship), HSC/MPP-surrounded spots as inter-  
226 spots (indicating the second closest relationship), and other distant spots (indicating nearly no  
227 interactive relationship) (Fig. 4a). For each niche cell type, analysis of enrichment score for  
228 different types of spots showed that EC with the highest score for intra-spots was close to  
229 HSCs/MPPs, which is consistent with a previous report<sup>13</sup>; hepatoblast and stromal cell with the  
230 highest scores respectively for inter-spots and other distant spots were less close to HSCs/MPPs;  
231 unexpectedly, macrophage with the higher score for intra- and inter-spots than that for other  
232 distant spots was considered as a novel niche component spatially close to HSCs/MPPs (Fig.  
233 4b). To quantitatively compare the interaction between HSCs/MPPs and different niche cells,  
234 we defined an enrichment fold based on the ratio of the enrichment score median for each spot  
235 type to the enrichment score median for all spots. Consequently, we found that macrophage  
236 showed a 11.52-fold enrichment in the intra-spots and a 1.31-fold in the inter-spots, EC showed  
237 a 1.62-fold enrichment in the intra-spots, while hepatoblast and stromal cell showed less  
238 enrichment in the intra-spots (Fig. 4c, d; Supplementary information, Fig. S7a). Furthermore,  
239 to validate the spatial relationship at nearly single-cell resolution, we analyzed the mouse E13.5  
240 FL ST data based on Stereo-seq, which is a sequencing-based spatially resolved transcriptomic  
241 technology with subcellular resolution<sup>48</sup>. We defined 20 bins as a spot (10-15  $\mu\text{m}$  in diameter),  
242 which may include 1-3 cell (s), and then annotated the spots (including intra-spots<sup>Stereo-seq</sup>, inter-  
243 spots<sup>Stereo-seq</sup> and other distant spots<sup>Stereo-seq</sup>) referring to the aforementioned pipeline. As a result,

244 we found that macrophages showed a high enrichment both in intra-spots<sup>Stereo-seq</sup> and inter-  
245 spots<sup>Stereo-seq</sup> (Supplementary information, Fig. S7b). Finally, the consistent result was validated  
246 by CSOmap<sup>49</sup>, an analytic method to reconstruct the cell spatial organization *de novo* based on  
247 scRNA-seq data (Supplementary information, Fig. S7c-f). Taken together, the results from three  
248 analytic methods of spatial information support that macrophage serve as an important niche  
249 cell with the closest relationship with HSCs/MPPs.

250 At molecular level, we examined the spatial expression of interactive signals predicted by  
251 CellPhoneDB analysis, and found that genes encoding ligands, such as MDK and PTN, were  
252 highly expressed in niche cells of intra-spots and inter-spots (Fig. 4e-i), and genes related to  
253 receptors, such as LRP1 and PTPRS, were enriched in HSCs/MPPs-localized spots (Fig. 4e-i).  
254 These results indicate that spatial proximity facilitates the signaling interactions for functionally  
255 supporting HSC/MPP expansion. Given that the intra-spots and inter-spots were characterized  
256 by spatially-proximal relationship among cells and enriched interactive signals, we defined  
257 them as expansion units, in which HSCs/MPPs located at the core of spots and interacted with  
258 surrounding niche cell spots (Fig. 4f, h, i). Taken together, we demonstrate that FL HSCs/MPPs  
259 expand in a number of units, in which macrophages and several growth factors, including MDK  
260 and PTN, are highly enriched.

261

### 262 **Functional validation of role of niche cells in promoting HSC/MPP expansion**

263 To determine how macrophages modulate HSC/MPP expansion in the FL, we firstly examined  
264 the spatial relationship between HSCs/MPPs and macrophages at E14.5. Immunofluorescence  
265 assay revealed two spatial patterns, one was that HSCs/MPPs attach proximal macrophages,

266 the other was that HSCs/MPPs are surrounded by macrophages (Fig. 5a-d). Of note, the latter  
267 pattern is similar to that between hematopoietic stem and progenitor cells and ECs in the FL  
268 equivalent of zebrafish<sup>50</sup>, suggesting that macrophages may promote HSC/MPP expansion via  
269 forming a ‘pocket-like’ architecture. Functionally, E14.5 HSCs/MPPs were co-cultured with  
270 macrophages or cultured in the defined medium supplemented with macrophage-derived MDK.  
271 As expected, we found that HSC/MPP expansion was enhanced in macrophage co-cultured or  
272 MDK-supplemented systems, suggesting that macrophages can facilitate HSC/MPP expansion  
273 via secreting MDK factor (Fig. 5e-g). Furthermore, to determine whether the depletion of  
274 macrophages within FL niche will affect HSC/MPP expansion, macrophages were firstly  
275 depleted by using apoptosis-inducing clodronate-liposomes (Supplementary information, Fig.  
276 S8a-d)<sup>36</sup>, and then we found that the absolute number of FL cells and the proportion of  
277 HSCs/MPPs (LSK cells and SLAM-LSK cells) were decreased at E14.5 (Fig. 5h-l).

278 Given that the FL is a transitory reservoir for both EMP- and HSC/MPP-derived  
279 macrophages<sup>51</sup>, we thus performed bioinformatic analysis, immunofluorescence imaging and  
280 co-culture assay to determine which type of macrophages are in close contact to HSCs/MPPs.  
281 Firstly, by performing analyses of signature gene expression, developmental trajectory, and  
282 transcriptomic correlation, we found that macrophage1 (Mac1) and macrophage2 (Mac2) were  
283 derived from HSCs/MPPs and EMPs, respectively (Supplementary information, Fig. S9a-e).  
284 Then, we examined the spatial relationship between macrophages (Mac1 and Mac2) and  
285 HSCs/MPPs by 10x Visium ST. As a result, we found that both Mac1 and Mac2 exhibited a  
286 high enrichment in the intra- and inter-spots (Supplementary information, Fig. S10a), indicating  
287 that they are both in close contact to HSCs/MPPs. Moreover, immunofluorescence imaging

288 showed that both Mac1 (marked by  $Ccr2^{52,53}$ ) and Mac2 (marked by Iba1 and  $LXR\alpha/\beta^{52,54}$ )  
289 exhibited an adjacent relationship with HSCs/MPPs (marked by Runx1, c-Kit and  $CD150^{13,31,55}$ )  
290 at E14.5 (Supplementary information, Fig. S10b-g). Finally, to examine the effect of Mac1 and  
291 Mac2 on the HSC/MPP expansion, we sorted  $F4/80^{low}$  macrophages  
292 ( $CD45^+CD11b^+F4/80^{low53,56}$ , similar to Mac1),  $F4/80^{high}$  macrophages  
293 ( $CD45^+CD11b^{low}F4/80^{high53,56}$ , similar to Mac2), and performed co-culture assay with mouse  
294 HSCs/MPPs (LSK) at E14.5, respectively. As a result, we found that HSC/MPP expansion was  
295 enhanced both in Mac1- and Mac2-co-cultured systems (Supplementary information, Fig.  
296 S10h). Taken together, these results suggest that both EMP- and HSC/MPP-derived  
297 macrophages play important roles in supporting HSC/MPP expansion.

298 In addition to macrophages, a meaningful proportion of HSC/MPP expansion units were also  
299 composed of three structural niche cells (Supplementary information, Fig. S7g-i). Among them,  
300 a closer spatial relationship between HSCs/MPPs and ECs was uncovered by 10x Visium ST  
301 (Fig. 4b-d, Supplementary information, Fig. S7a). To characterize EC-forming niche of  
302 HSCs/MPPs in detail, we detected their spatial relationship. Immunofluorescence assay  
303 revealed that HSCs/MPPs were surrounded by ECs (Fig. 6a, b), and most of the HSCs/MPPs  
304 were close to arterial portal vessels labeled with EphrinB2<sup>13</sup>, with a few HSCs/MPPs residing  
305 around hepatic veins labeled with EphB4<sup>57</sup> at E14.5 (Fig. 6c, d). These results indicate that  
306 HSCs/MPPs show preferential spatial association adjacent to a putative portal vessel niche in  
307 the FL. To functionally determine whether the predicted interactive signals derived from  
308 structural niche cells can regulate HSC/MPP expansion, we performed HSC/MPP expansion  
309 assay at E14.5 in the defined medium supplemented with IGF1, IGF2, HGF, and PTN,

310 respectively. Given that the function of IGFs is regulated by their carrier proteins, IGFBPs<sup>58,59</sup>,  
311 we also examined the role of IGFBP1/5/7, whose gene expression was enriched in hepatoblasts,  
312 stromal cells, and ECs, respectively (Fig. 6e). Consequently, the efficiency of supporting  
313 HSC/MPP expansion in IGFBP5- and PTN-supplemented culture systems was higher than that  
314 in IGF1-, IGF2-, HGF-, IGFBP1- and IGFBP7-supplemented culture systems (Fig. 6f-h). Taken  
315 together, functional analysis validates the potential cell-cell interactions and underlying  
316 molecular mechanisms supporting HSC/MPP expansion.

317

### 318 **Cross-species analysis of FL hematopoiesis between mice and humans**

319 To analyze the conservation and divergence of FL hematopoiesis between mice and humans,  
320 we compared our scRNA-seq data with a recently published scRNA-seq atlas of the human  
321 FL<sup>15</sup>. A total of 6,325 single cells from the human FL at 11 post-conception weeks (PCW) and  
322 8,404 cells from the mouse FL at E14.5 were subjected to unsupervised UMAP analysis (Fig.  
323 7a; Supplementary information, Fig. S11a). The integrative analysis showed that the FL cell  
324 types and HSC/MPP multilineage (erythrocyte/myelocyte/lymphocyte) differentiation routes  
325 were well mixed between these two species (Fig. 7b). Moreover, comparison of mouse and  
326 human FL cell types showed that most cell types were highly correlated (Supplementary  
327 information, Fig. S11b). Taken together, these data reveal conserved cell types and  
328 hematopoietic differentiation routes between mouse and human FL.

329 To compare the transcriptome features of FL HSCs/MPPs between mice and humans, we  
330 performed DEG analysis between HSCs/MPPs and other cell clusters for each species and  
331 identified 39 canonical HSC/MPP signature genes that are conserved in humans and mice

332 (Supplementary information, Fig. S11c). Moreover, we performed GO analysis of the DEGs  
333 between mouse and human HSCs/MPPs. The results showed that the GO terms related to  
334 “regulation of DNA damage response,” “regulation of interleukin-6 biosynthetic process,” and  
335 “regulation of telomerase activity” were enriched in human HSCs/MPPs (Fig. 7c), supporting  
336 the idea that human HSCs/MPPs are susceptible to DNA damage<sup>60,61</sup>. By contrast, the GO terms  
337 “positive regulation of inflammatory response,” “cellular response to type I interferon,” and  
338 “negative regulation of viral entry into host cells” were enriched in mouse HSCs/MPPs,  
339 supporting the notion that mouse HSCs/MPPs are responsive to inflammatory signals (Fig.  
340 7d)<sup>62</sup>. Given the different living environments between mice and humans, mouse HSCs/MPPs  
341 may be more resistant to pathogen-derived inflammation, whereas human HSCs/MPPs are  
342 likely more susceptible to radiation-induced DNA damage. The presence of these divergent  
343 transcriptome features of HSCs/MPPs therefore indicates that despite overall similarity, there  
344 also exist species-specific mechanisms of the adaptive response to external stimuli.

345 To determine whether the mechanisms of HSC/MPP expansion in mice are conserved in  
346 humans, we also constructed an HSC/MPP–niche cell interaction network in the human FL  
347 using CellPhoneDB. We found that HSCs/MPPs displayed the stronger interactions with  
348 macrophages and ECs than other two niche cells (Fig. 7e), which was also validated by  
349 CSOmap analysis (Supplementary information, Fig. S11d, e). In addition, we found that the  
350 interactions related to cell growth, cell adhesion, cytokine, and Notch signaling identified in  
351 mice also existed in humans (Fig. 7f). Functionally, we performed immunofluorescence  
352 imaging and validated the cell-cell interaction between macrophages (marked by CD68) and  
353 HSCs/MPPs (marked by CD34) in human FL at 11 PCW (Fig. 7g-i); meanwhile, human cord

354 blood (CB) CD34<sup>+</sup> HSCs/MPPs were co-cultured with mouse macrophages. After four-day co-  
355 culture, we found that the number of co-cultured CB CD34<sup>+</sup> HSCs/MPPs was more than (1.7  
356 folds) that of CB HSCs/MPPs without macrophage co-culture, supporting that macrophages  
357 play a conserved role in supporting human HSC/MPP expansion (Fig. 7j). Taken together, these  
358 data are consistent with a model whereby many mechanisms of FL HSC expansion are  
359 conserved between humans and mice, but there are also species-specific transcriptome  
360 signatures in HSCs/MPPs.

361

## 362 **DISCUSSION**

363 Using a high-throughput scRNA-seq and high-spatial-resolution ST framework, we generated  
364 an integrated spatiotemporal transcriptome atlas of FL in mice (Supplementary information,  
365 Fig. S12). scRNA-seq and functional analyses revealed that CD93 can be applied to purify a  
366 subset with enhanced stem cell properties from heterogeneous FL HSCs/MPPs. Given that  
367 CD93-marked type 1 HSC precursors in mouse AGM region do not show enhanced  
368 reconstitution ability than the counterparts after co-culture with stromal cell<sup>63</sup>, we reason that  
369 hematopoietic cell heterogeneity characterized by CD93 may be cell-type- and developmental  
370 stage-dependent. Importantly, by integrating transcriptome, immunostaining, and functional  
371 analyses, we identified the ‘pocket-like’ units for HSC/MPP expansion, termed as HSC PLUS.  
372 Furthermore, although cross-species comparison of the FL cell atlas between mice and humans  
373 showed some divergent transcriptome signatures of HSCs/MPPs indicative of a species-specific  
374 mechanism of the adaptive response to external stimuli, the overall transcriptional similarity as  
375 well as conserved expansion mechanisms of HSCs/MPPs underscores the values of mouse

376 models to provide guidance for the expansion of functional human HSCs/MPPs *ex vivo*.

377 A profound understanding of cellular and molecular mechanisms underlying HSC/MPP  
378 expansion is essential for establishing protocols of HSC/MPP expansion *ex vivo*. Previous  
379 studies have suggested that FL niche cells can support HSC/MPP expansion via paracrine  
380 signaling. For instance, ECs can secrete SCF, ANGPTL2, and IGF2 for HSC expansion<sup>13</sup>;  
381 hepatoblasts support HSC/MPP expansion by secreting ANGPTL3, IGF2, SCF, and TPO<sup>12,64</sup>;  
382 and stromal cells produce ANGPTL2/3 and IGF2 for HSC/MPP expansion<sup>39,65</sup>. However, how  
383 these different types of cells interact with each other to form distinct functional tissues/organs  
384 remains unclear. By integrative analysis of spatiotemporal transcriptome atlas and functional  
385 experiments, we, for the first time, defined the HSC PLUS as the smallest functional units of  
386 FL. Within the HSC PLUS, macrophages and expansion-favoring factors MDK, PTN, and  
387 IGFBP5 are enriched. Although the close spatial relationships between macrophages/ECs and  
388 HSCs/MPPs was also revealed by CSOmap analysis in human FL, further functional validation  
389 of the conserved mechanisms is warranted in future investigations. Taken together, our resource  
390 deepens the understanding of the crosstalk between HSCs/MPPs and niche cells, and provides  
391 novel insights into the generation of HSC PLUS-based culture system for HSCs/MPPs *ex vivo*.

392 Macrophages play an important role in immune defense, however, extensive studies have  
393 demonstrated their multiple functional roles beyond immune defense. For example,  
394 macrophages repair the ruptured brain vessels in zebrafish via adhesion and mechanical traction  
395 <sup>66</sup>; in mouse aorta, macrophages secrete matrix metalloproteinase 9 to control the collagen  
396 production and prevent arterial stiffness<sup>67</sup>. Our immunofluorescence, integrative  
397 transcriptomics, and functional analyses identify an uncharacterized role of FL-resident

398 macrophages in facilitating HSC/MPP expansion. Interestingly, macrophages form a ‘pocket-  
399 like’ architecture surrounding inside HSCs/MPPs, which is architecturally similar to EC  
400 ‘pocket’ observed in E11.5 mouse FL<sup>50</sup>. Of note, the existence of ‘pocket-like’ architecture  
401 formed by different niche cells may be partially explained by that a specialized  
402 microenvironment could effectively enhance cell-cell interaction by increasing the  
403 concentration of local signaling molecules<sup>50</sup>, such as Ccl21 from ECs<sup>55</sup> and MDK from  
404 macrophages (in this study). Taken together, our unbiased characterization of HSC/MPP niche  
405 components updates the paradigm that HSCs/MPPs preferentially reside in the perivascular  
406 niche and are regulated by ECs, hepatoblasts, and stromal cells<sup>10-13,50</sup>.

407 In summary, our findings characterize HSC/MPP heterogeneity, expansion-favoring factors  
408 and architectural basis, and conserved expansion mechanisms in both mice and humans, which  
409 provides a valuable resource for studying HSC/MPP expansion. Further analysis of this  
410 resource will help to elucidate the mechanism underlying hematological malignancies of fetal  
411 origin.

412 **MATERIALS AND METHODS**

413 **Experimental model**

414 Mouse lines

415 Wild-type C57BL/6 mice were purchased from SPF (Beijing) Biotechnology Co., Ltd. CD93  
416 genetic mutant mice were generated as previously described<sup>68</sup>. B6.SJL (CD45.1) mice were  
417 purchased from the Institute of Laboratory Animal Science (ILAS), Chinese Academy of  
418 Medical Sciences (CAMS). All mice were bred under specific pathogen-free conditions (animal  
419 license number: SYXK (Beijing) 2018-0021). For transplantation assays, male CD45.1 mice  
420 were crossed with female CD45.2 mice to obtain CD45.1/.2 embryos; the morning that the  
421 vaginal plug was detected was defined as embryonic day (E) 0. The present study was approved  
422 by the Ethical Review Committee of the Institute of Zoology, Chinese Academy of Sciences,  
423 China.

424 Human samples

425 Human embryos were obtained following electively terminated pregnancies at Haidian  
426 Maternal & Child Health Hospital in Beijing. All experiments were performed in accordance  
427 with protocols approved by the Peking University Institutional Review Board (PUIRB)  
428 (certificate number: IRB00001052-18083)<sup>69</sup> and the Ethics Committee of the Institute of  
429 Zoology, Chinese Academy of Sciences. Written informed consent was obtained before sample  
430 collection.

431 Human cord blood (CB) samples were collected from healthy volunteers after informed  
432 consents obtained. All experiments were performed in accordance with protocols approved by  
433 the Research Ethics Committee of Beijing Institute of Transfusion Medicine and the Ethics  
434 Committee of the Institute of Zoology, Chinese Academy of Sciences. CD34<sup>+</sup> HSCs/MPPs from  
435 human CB were performed in accordance with protocols<sup>70,71</sup>.

436 **Flow cytometry**

437 Single-cell suspensions from the FL were prepared by mechanical dissociation, and the cells  
438 were stained for 30 min at 4°C. Antibodies used in this study included those against: Lineage-  
439 FITC (Biolegend, 133302), 7-AAD (Biolegend, 420404), CD117-APC (eBioscience, 17-1171-  
440 82), CD117-PE-Cyanine5 (eBioscience, 15-1171-81), CD117- APC-eFluor 780 (eBioscience,  
441 47-1171-82), Ly-6A/E-PE-Cyanine7 (eBioscience, 25-5981-81), CD135-PE-Cyanine5  
442 (eBioscience, 15-1351-82), CD135-APC (Biolegend, 135309), CD45.1-FITC (eBioscience,  
443 11-0451-81), CD45.2-PE-Cyanine7 (eBioscience, 25-0454-80), CD3e-APC (eBioscience, 17-  
444 0031-81), B220-PE (eBioscience, 12-0452-81), CD11b-APC (eBioscience, 17-0112-81),  
445 Ly6G/Ly-6C-PE (eBioscience, 12-5931-81), CD150-PE (eBioscience, 12-1502-82), CD48-  
446 APC-eFluor780 (eBioscience, 47-0481-82), CD93-APC (eBioscience, 17-5892-81), CD45-  
447 FITC (eBioscience, 11-0451-82), CD68- PE-Cyanine7 (eBioscience, 25-0681-80), CD34-APC  
448 (BD, 560940) and APC-Cyanine7-F4/80 (Biolegend, 123117). 7-AAD viability staining  
449 solution was used to exclude dead cells. Flow cytometry was performed using MoFlo XDP  
450 (Beckman Coulter) and the analysis was carried out with Flowjo (vX.7.0).

451 **HSC/MPP cell culture**

452 100 HSCs/MPPs from E14.5 FL, including Lin<sup>-</sup>Sca-1<sup>+</sup>c-Kit<sup>+</sup> (LSK), Flit3<sup>-</sup>LSK, CD150<sup>+</sup>CD48<sup>-</sup>  
453 LSK (SLAM-LSK), were alone cultured in 100 µL StemSpan medium in a well of 96 U-well  
454 plate for 15 days. The culture medium was supplemented with 50 ng/mL SCF (Peprotech), 30  
455 ng/mL FLT3L (Peprotech), 20 ng/mL TPO (Peprotech), and 10 ng/mL IL-6 (Peprotech). The  
456 expansion medium was supplemented with 50 ng/mL IGF1, IGF2, IGFBP1, IGFBP5, IGFBP7,  
457 PTN, MDK, respectively.

458 E14.5 HSCs/MPPs (LSK cells) at a density of  $2 \times 10^3$  cells were co-cultured with  $2 \times 10^4$   
459 F4/80<sup>low</sup> macrophages (CD45<sup>+</sup>CD11b<sup>+</sup>F4/80<sup>low</sup>), F4/80<sup>high</sup> macrophages  
460 (CD45<sup>+</sup>CD11b<sup>low</sup>F4/80<sup>high</sup>) or macrophages (containing half of F4/80<sup>low</sup> and half of F4/80<sup>high</sup>  
461 macrophages) in 500  $\mu$ L MyeloCult M5300 medium in a well of 24-well plate for 4 days. The  
462 culture medium was supplemented with 50 ng/mL SCF (Peprotech), 30 ng/mL FLT3L  
463 (Peprotech), 20 ng/mL TPO (Peprotech), and 10 ng/mL IL-6 (Peprotech).

464 Human CB CD34<sup>+</sup> HSCs/MPPs at a density of  $2 \times 10^3$  cells were co-cultured with  $2 \times 10^4$   
465 mouse macrophages in 500  $\mu$ L StemSpan medium in a well of 24-well plate for 4 days. The  
466 culture medium was supplemented with 50 ng/mL Recombinant Human SCF (Peprotech), 50  
467 ng/mL FLT3L (Peprotech), 50 ng/mL TPO (Peprotech).

#### 468 **Clodronate-liposome treatment**

469 For the clodronate-liposome treatment, pregnant females were injected with Clodronate-  
470 liposome and Control-liposome (CP-005-005, LIPOSOME) as dose of 1mg 20g<sup>-1</sup> mouse  
471 body weight at E11.5, E12.5 and E13.5, respectively, and the macrophage depletion and FL  
472 HSC/MPP phenotype were measured at E14.5.

#### 473 **Immunofluorescence**

474 Immunofluorescence assay for embryos was performed as previously described<sup>72</sup>. The E14.5  
475 embryos or human FL (11 PCW) were fixed in 4% paraformaldehyde/PBS overnight at 4°C.  
476 After gradient dehydration in 15% and 30% sucrose/PBS at 4°C, these embryos were embedded  
477 and frozen in OCT overnight at -80°C. The following day, embryos were sectioned to 10- $\mu$ m-  
478 thick slides and blocked for 2 h at room temperature with 5% BSA/PBS containing 0.3% Triton  
479 X-100. After washing three times in PBS, 15 min/time on an orbital shaker, the slides were

480 incubated overnight at 4°C with primary antibodies diluted in 1% BSA/PBS. The following day,  
481 the slices were washed three times in PBS containing 0.1% Tween-20, 15 min/time on an orbital  
482 shaker, and incubated for 2 h at room temperature with secondary antibodies diluted in 1%  
483 BSA/PBS. Nuclei were stained with Hoechst 33342 (Invitrogen) and immunofluorescence  
484 images were obtained using a laser scanning confocal microscope (A1; Nikon). The primary  
485 antibodies used in the assays included those against: Runx1 (1:800; abcam), CD150 (1:200,  
486 BD), CD150 (1:200, Biolegend), c-Kit (1:300; BD), c-Kit (1:200; Biolegend), Hlf (1:100,  
487 ABclonal), Mecom (1:200, ABclonal), EphrinB2 (1:300; R&D), Ephb4 (1:300; R&D), Lyve1  
488 (1:800; R&D), F4/80 (1:800, Santa Cruz), LXR $\alpha/\beta$  (1:500, Santa Cruz), Iba1 (1:500, Santa  
489 Cruz), Ccr2 (1:250; abcam), human anti-CD34 antibody (1:250; abcam), human anti-CD68  
490 antibody (1:200; Biolegend). The secondary antibodies used in the assays included goat anti-  
491 rabbit IgG Alexa Fluor 488 (1:800; Life Technologies), goat anti-rabbit IgG Alexa Fluor 594  
492 (1:800; Life Technologies), donkey anti-rat IgG Alexa Fluor 488 (1:800; Life Technologies),  
493 goat anti-rat IgG Alexa Fluor 594 (1:800; Life Technologies), goat anti-mouse IgG Alexa Fluor  
494 488 (1:800; Life Technologies), goat anti-mouse IgG Alexa Fluor 555 (1:800; Life  
495 Technologies) and donkey anti-goat IgG Alexa Fluor 647 (1:300; Life Technologies),

#### 496 **Colony-forming unit (CFU) culture assay**

497 Single-cell suspensions of sorted E14.5 HSCs/MPPs in combination of CD93 and other  
498 HSC/MPP markers were cultured in M3434 medium (Stem Cell Technologies, 03434) at 37°C  
499 with 5% CO<sub>2</sub> for 10 days. Subsequently, the number of each type of colony, including CFU-E,  
500 CFU-GM, and CFU-GEMM, was counted based on morphology. More than three groups of  
501 independent experiments were analyzed. CFU-E, CFU-erythroid; CFU-GEMM, CFU-

502 granulocyte, erythroid, macrophage, megakaryocyte; CFU-GM, CFU-granulocyte,  
503 macrophage.

#### 504 **Transplantation assay**

505 CD45.2 recipients received a split lethal dose (9 Gy) of X-ray irradiation (RS2000). For the  
506 primary transplantation assay, a total of 500 CD93<sup>+</sup>HSCs/CD93<sup>-</sup>HSCs or 2,000  
507 LSK/CD93<sup>+</sup>LSK cells were sorted from E14.5 FL along with  $4 \times 10^4$  CD45.2 nucleated bone  
508 marrow (BM) cells and intravenously injected into the tail vein of the recipients. For the  
509 secondary transplantation assay,  $1 \times 10^6$  BM cells from donor mice were mixed with  $4 \times 10^4$   
510 CD45.2 nucleated BM cells and intravenously injected into the tail vein of the recipients. The  
511 chimerism and the multi-lineage reconstitution ability were analyzed using peripheral blood  
512 (PB) from the recipients.

#### 513 **Western blotting**

514 Western blotting was performed as previously described<sup>72</sup>. The protein extracted from E14.5  
515 fetal liver cells with cell lysis buffer (10 mM Tris-HCl, pH 8.0, 10 mM NaCl, and 0.5% NP-40)  
516 containing protease inhibitor (no.04693116001; Roche). The protein level of CD93 was  
517 detected using the following antibodies: anti- $\beta$  actin (1:2,000, Cell Signaling Technology).  
518 Anti-CD93 (1:1,000, abcam).

#### 519 **Cell preparation for single-cell RNA-sequencing (scRNA-seq)**

520 Fluorescence-activated cell sorting was performed at four time points to separately sort  
521 hematopoietic cells (HCs), endothelial cells (ECs), and non-hematopoietic/non-endothelial  
522 cells (NCs) from the FL, and subsequently pooled them together for sequencing. At E11.5,  
523 CD45<sup>+</sup>HCs<sup>9,73</sup> and CD45<sup>-</sup> non-HCs were pooled together for sequencing. At E12.5, E13.5, and

524 E14.5, LSK cells<sup>74,75</sup>, CD45<sup>+</sup>HCs, CD45<sup>-</sup>CD31<sup>+</sup>ECs<sup>76</sup>, and CD45<sup>-</sup>CD31<sup>-</sup> NCs were pooled  
525 together for sequencing.

#### 526 **Processing of scRNA-seq data**

527 To capture individual cells, we utilized the Chromium Single Cell 2' Reagent Version 1 Kit (10x  
528 Genomics). The quality of the sequencing reads was evaluated by FastQC and MultiQC. Cell  
529 Ranger v2.2.0 was used to align the sequencing reads to the mm10 mouse reference genome  
530 and quantitate the expression of transcripts in each cell. R v3.6.0 and the package Seurat v3.1.2  
531 were used for the downstream analyses. Cells with fewer than 250 detected genes, less than 500  
532 unique molecular identifiers (UMIs), or more than 10% mitochondrial UMIs were removed.  
533 Finally, we detected an average of 3,503 genes per cell.

#### 534 **Batch correction and dimension reduction**

535 To minimize technical variability due to sample collection time points while preserving  
536 biological variation, two functions in Seurat, FindIntegrationAnchors and IntegrateData, were  
537 used for batch correction among cells at the four embryonic stages. Specifically, only principal  
538 components analysis (PCA) and PCA-dependent analyses were performed using batch-  
539 corrected data.

540 Dimension reduction includes three stages of analysis: selection of variable genes  
541 (FindVariableGene), PCA (RunPCA, from variable genes), and uniform manifold  
542 approximation and projection (UMAP). After quantity control, we obtained 32,449 high-quality  
543 single cells for further analysis. Subsequently, we performed PCA using the 2,000 most variable  
544 genes selected by the FindIntegrationAnchors function. The top 30 principal components (PCs)  
545 were selected for UMAP to obtain bidimensional coordinates for each cell.

546 To dissect the potential relationship among HSCs/MPPs, progenitors, and macrophages, we  
547 also performed PHATE analysis using the same 2,000 genes.

#### 548 **Unsupervised clustering and annotation**

549 We performed the FindNeighbors and FindClusters functions (resolution = 0.5) to cluster cells  
550 using the Louvain algorithm based on the top 30 PCs. The final number of cell clusters was  
551 found to be 21 by selecting a resolution of 0.5. The known markers used for cell cluster  
552 annotation are listed in **Table S1**.

#### 553 **Identification of differentially expressed genes**

554 We used the FindAllMarkers function (logfc. threshold = log(1.2)) based on normalized data to  
555 identify differentially expressed genes (DEGs). *P*-value adjustment was performed using  
556 Bonferroni correction based on the total number of genes in the dataset. DEGs with adjusted *P*-  
557 values > 0.05 were filtered out. GO analyses were performed using the R package cluster  
558 profiler<sup>77</sup>.

#### 559 **Cell-cell interaction analysis**

560 CellPhoneDB<sup>33,34</sup> was used to infer enriched ligand–receptor interactions based on the gene  
561 expression of a ligand in one cell type and its receptor in another cell type. Selected  
562 ligand–receptor pairs enriched between HSCs and niche cells or macrophages were visualized.  
563 We only considered the ligands expressed in more than 20%, and receptors expressed in more  
564 than 4%, of cells in one cluster.

#### 565 **10x Visium Spatial Transcriptomics (ST)**

##### 566 *Staining and imaging*

567 E14.5 embryos were embedded in tissue-Tek (OCT) and snap-frozen using dry ice slurry.

568 Cryosections were cut at 10- $\mu$ m thickness, mounted onto the GEX arrays. Sections were placed  
569 on Thermocycler Adaptor with the active surface facing up and incubate 1 min at 37°C, and  
570 fixed for 30 min with methyl alcohol in -20°C, followed by staining with H&E (Eosin, Dako  
571 CS701, Hematoxylin Dako S3309, bluing buffer CS702). The brightfield images were taken on  
572 a Leica DMI8 whole-slide scanner at 10x resolution.

### 573 ***Permeabilization and reverse transcription***

574 Visum spatial gene expression was processed using Visum spatial gene expression slide and  
575 Reagent Kit (10x Genomics, PN-1000184). For each well, Slide Cassette was used to create  
576 leakproof wells for adding reagents. 70  $\mu$ L Permeabilization enzyme were added and  
577 incubated at 37°C for 20 min. Each well was washed with 100  $\mu$ L SSC, and 75  $\mu$ L reverse  
578 transcription Master Mix was added for cDNA Synthesis.

### 579 ***cDNA library preparation for sequencing***

580 At the end of first-strand synthesis, remove RT Master Mix from the wells. Add 75  $\mu$ L 0.08  
581 M KOH and incubate 5 min at room temperature, then remove the KOH from wells and  
582 washed with 100  $\mu$ L EB buffer. Add 75  $\mu$ L Second Strand Mix to each well for second-strand  
583 synthesis. cDNA amplification was performed on a S1000<sup>TM</sup> Touch Thermal Cycler (Bio  
584 Rad). According to the manufacture's introduction, Visum spatial libraries were constructed  
585 using Visum spatial Library construction kit (10x Genomics, PN-1000184). The libraries were  
586 finally sequenced using an Illumina Novaseq6000 sequencer with a sequencing depth of at  
587 least 100,000 reads per spot with pair-end 150 bp (PE150) reading strategy (performed by  
588 CapitalBio Technology, Beijing).

### 589 ***Processing of the spatial transcriptomics data***

590 To annotate spots, we applied the integration workflow introduced in Seurat v3, which enables  
591 the probabilistic transfer of cell types from the scRNA-seq data to the ST data. Specifically, we  
592 first identified pairwise correspondences between single cells and single spots to quantify the  
593 batch effect. Each spot was then annotated based on the transcriptomic similarity between spots  
594 and cell types in the scRNA-seq dataset. This probabilistic transfer procedure was implemented  
595 using the FindTransferAnchors (dims = 1:30) and TransferData (dims = 1:30) functions in  
596 Seurat with the combination of top 100 DEGs of each cell type.

### 597 **Cross-species analysis of FL in between mouse and human**

598 We obtained single-cell transcriptome data of human FL from ArrayExpress under the accession  
599 code E-MTAB-7407. Firstly, we analyzed gene expression matrices of 6,325 human FL cells at  
600 11 post-conception weeks and 8,404 mouse FL cells at E14.5 after filtering low-quality cells.  
601 We then filtered mouse–human ortholog genes based on the Mouse Genome Informatics (MGI)  
602 database ([http://www.informatics.jax.org/downloads/reports/HMD\\_HumanPhenotype.rpt](http://www.informatics.jax.org/downloads/reports/HMD_HumanPhenotype.rpt)),  
603 and obtained 13,819 homologous genes with a one-to-one translation between humans and mice  
604 for further analysis. Next, the merge function was used to combine human and mouse FL cells,  
605 and further analysis was performed including UMAP, differential expression, and Pearson  
606 correlation using the same methods described above.

### 607 **Quantitation and statistical analysis**

608 GraphPad Prism 6 was used to analyze the data. Values are presented as the mean  $\pm$  SEM. A  
609 Student's unpaired two-tailed t-test was applied for comparisons unless otherwise indicated.

610

### 611 **DATA AVAILABILITY**

612 The scRNA-seq and 10x Visium ST datasets generated in the present study are available at  
613 <https://bigd.big.ac.cn/gsub/> in BIG Submission Portal, under the accession number  
614 CRA002489 and CRA003651, respectively. The E13.5 Stereo-seq dataset used in the present  
615 study is kindly provided by Prof. Xun Xu and Prof. Longqi, Liu.

616

## 617 **ACKNOWLEDGMENTS**

618 We thank Yiwei Lai (BGI-ShenZhen, Shenzhen, China) for data transmission of E13.5 Stereo-  
619 seq dataset. This work was supported by grants from the National Key Research and  
620 Development Program of China (2018YFA0800200, 2018YFA0801000, 2016YFA0100500 to  
621 F.L., and 2016YFA0100103 to C.L.), the Strategic Priority Research Program of the Chinese  
622 Academy of Sciences, China (XDA16010207 to F.L.), the National Natural Science Foundation  
623 of China (31830061, 81530004, 31425016 to F.L., and 31871266 to C.L.), and NSFC Key  
624 Research Grant 71532001 (to C.L.). Part of the data analysis was performed on the High-  
625 Performance Computing Platform of the Center for Life Sciences, Peking University.

626

## 627 **AUTHORSHIP CONTRIBUTIONS**

628 S.G. and F.L. conceived the project, analyzed the data, and wrote the paper; S.G. performed  
629 most of the experiments with help from Y.Z., G.L., B.H., D.M., and L.W.; Q.S. and Z.K.  
630 performed the bioinformatics analysis under the guidance of C.L.; J.J. provided CD93 genetic  
631 mutant mice; X.F. provided human CB sample; C.X. provided human FL sample; X.X. and L.L.  
632 provided E13.5 FL Stereo-seq dataset; B.G. interpreted the data and assisted with the  
633 manuscript. All authors read and approved the final manuscript.

634

635 **CONFLICT OF INTEREST DISCLOSURES**

636 The authors declare no competing interests.

637 **REFERENCES**

- 638 1 Yamamoto, R. *et al.* Clonal analysis unveils self-renewing lineage-restricted  
639 progenitors generated directly from hematopoietic stem cells. *Cell* **154**, 1112–  
640 1126, doi:10.1016/j.cell.2013.08.007 (2013).
- 641 2 Wilkinson, A. C., Igarashi, K. J. & Nakauchi, H. Haematopoietic stem cell  
642 self-renewal in vivo and ex vivo. *Nat Rev Genet* **21**, 541–554,  
643 doi:10.1038/s41576-020-0241-0 (2020).
- 644 3 Calvanese, V. *et al.* MLLT3 governs human haematopoietic stem-cell self-renewal  
645 and engraftment. *Nature* **576**, 281–286, doi:10.1038/s41586-019-1790-2 (2019).
- 646 4 Wilkinson, A. C. *et al.* Long-term ex vivo haematopoietic-stem-cell expansion  
647 allows nonconditioned transplantation (vol 571, pg 117, 2019). *Nature* **571**,  
648 doi:10.1038/s41586-019-1395-9 (2019).
- 649 5 McGrath, K. E., Frame, J. M. & Palis, J. Early hematopoiesis and macrophage  
650 development. *Semin Immunol* **27**, 379–387, doi:10.1016/j.smim.2016.03.013 (2015).
- 651 6 Hoeffel, G. & Ginhoux, F. Ontogeny of Tissue-Resident Macrophages. *Front*  
652 *Immunol* **6**, 486, doi:10.3389/fimmu.2015.00486 (2015).
- 653 7 Ema, H. & Nakauchi, H. Expansion of hematopoietic stem cells in the developing  
654 liver of a mouse embryo. *Blood* **95**, 2284–2288, doi:DOI  
655 10.1182/blood.V95.7.2284.007k14\_2284\_2288 (2000).
- 656 8 Mikkola, H. K. A. & Orkin, S. H. The journey of developing hematopoietic stem  
657 cells. *Development* **133**, 3733–3744, doi:10.1242/dev.02568 (2006).
- 658 9 Rybtsov, S., Ivanovs, A., Zhao, S. L. & Medvinsky, A. Concealed expansion of  
659 immature precursors underpins acute burst of adult HSC activity in foetal  
660 liver. *Development* **143**, 1284–1289, doi:10.1242/dev.131193 (2016).
- 661 10 Lee, Y., Leslie, J., Yang, Y. & Ding, L. Hepatic stellate and endothelial  
662 cells maintain hematopoietic stem cells in the developing liver. *J Exp Med*  
663 **218**, doi:10.1084/jem.20200882 (2021).
- 664 11 Swain, A., Inoue, T., Tan, K. S., Nakanishi, Y. & Sugiyama, D. Intrinsic and  
665 extrinsic regulation of mammalian hematopoiesis in the fetal liver. *Histol*  
666 *Histopathol* **29**, 1077–1082, doi:10.14670/HH-29.1077 (2014).
- 667 12 Schmelzer, E. Hepatic progenitors of the fetal liver: Interactions with  
668 hematopoietic stem cells. *Differentiation* **106**, 9–14,  
669 doi:10.1016/j.diff.2019.02.005 (2019).
- 670 13 Khan, J. A. *et al.* Fetal liver hematopoietic stem cell niches associate with  
671 portal vessels. *Science* **351**, 176–180, doi:10.1126/science.aad0084 (2016).
- 672 14 Han, X. *et al.* Mapping the Mouse Cell Atlas by Microwell-Seq. *Cell* **172**, 1091–  
673 1107 e1017, doi:10.1016/j.cell.2018.02.001 (2018).
- 674 15 Popescu, D. M. *et al.* Decoding human fetal liver haematopoiesis. *Nature* **574**,  
675 365–371, doi:10.1038/s41586-019-1652-y (2019).
- 676 16 Stahl, P. L. *et al.* Visualization and analysis of gene expression in tissue  
677 sections by spatial transcriptomics. *Science* **353**, 78–82,  
678 doi:10.1126/science.aaf2403 (2016).
- 679 17 McKinney-Freeman, S. *et al.* The transcriptional landscape of hematopoietic

680 stem cell ontogeny. *Cell Stem Cell* **11**, 701-714,  
681 doi:10.1016/j.stem.2012.07.018 (2012).

682 18 Gao, S. & Liu, F. Fetal liver: an ideal niche for hematopoietic stem cell  
683 expansion. *Sci China Life Sci* **61**, 885-892, doi:10.1007/s11427-018-9313-4  
684 (2018).

685 19 Becht, E. *et al.* Dimensionality reduction for visualizing single-cell data  
686 using UMAP. *Nat Biotechnol* **37**, 38-+, doi:10.1038/nbt.4314 (2019).

687 20 Zhang, Y. *et al.* PR-domain-containing Mds1-Evil is critical for long-term  
688 hematopoietic stem cell function. *Blood* **118**, 3853-3861, doi:10.1182/blood-  
689 2011-02-334680 (2011).

690 21 Yokomizo, T. *et al.* Hlf marks the developmental pathway for hematopoietic  
691 stem cells but not for erythro-myeloid progenitors. *J Exp Med* **216**, 1599-1614,  
692 doi:10.1084/jem.20181399 (2019).

693 22 Huang, K. L. *et al.* A common haplotype lowers PU.1 expression in myeloid  
694 cells and delays onset of Alzheimer's disease. *Nat Neurosci* **20**, 1052-1061,  
695 doi:10.1038/nn.4587 (2017).

696 23 Tober, J. *et al.* Maturation of hematopoietic stem cells from prehematopoietic  
697 stem cells is accompanied by up-regulation of PD-L1. *J Exp Med* **215**, 645-659,  
698 doi:10.1084/jem.20161594 (2018).

699 24 Hamey, F. K. & Gottgens, B. Machine learning predicts putative hematopoietic  
700 stem cells within large single-cell transcriptomics data sets. *Exp Hematol*  
701 **78**, 11-20, doi:10.1016/j.exphem.2019.08.009 (2019).

702 25 Moon, K. R. *et al.* Visualizing structure and transitions in high-dimensional  
703 biological data. *Nat Biotechnol* **37**, 1482-1492, doi:10.1038/s41587-019-0336-3  
704 (2019).

705 26 Jordan, C. T., McKearn, J. P. & Lemischka, I. R. Cellular and developmental  
706 properties of fetal hematopoietic stem cells. *Cell* **61**, 953-963,  
707 doi:10.1016/0092-8674(90)90061-i (1990).

708 27 Rebel, V. I. *et al.* A comparison of long-term repopulating hematopoietic stem  
709 cells in fetal liver and adult bone marrow from the mouse. *Exp Hematol* **24**,  
710 638-648 (1996).

711 28 Harrison, D. E., Zhong, R. K., Jordan, C. T., Lemischka, I. R. & Astle, C. M.  
712 Relative to adult marrow, fetal liver repopulates nearly five times more  
713 effectively long-term than short-term. *Exp Hematol* **25**, 293-297 (1997).

714 29 Zeigler, F. C., Bennett, B., Jordan, C. T., Bauer, K. & Matthews, W. Cellular  
715 and Molecular Characterization of the Role of the Flk-2 Flt-3 Receptor  
716 Tyrosine Kinase in Hematopoietic Stem-Cells. *Blood* **84**, A415-A415 (1994).

717 30 Kim, I., He, S. H., Yilmaz, O. H., Kiel, M. J. & Morrison, S. J. Enhanced  
718 purification of fetal liver hematopoietic stem cells using SLAM family  
719 receptors. *Blood* **108**, 737-744, doi:10.1182/blood-2005-10-4135 (2006).

720 31 Toyama, H., Arai, F., Hosokawa, K., Ikushima, Y. M. & Suda, T. N-cadherin+  
721 HSCs in fetal liver exhibit higher long-term bone marrow reconstitution  
722 activity than N-cadherin- HSCs. *Biochem Biophys Res Commun* **428**, 354-359,  
723 doi:10.1016/j.bbrc.2012.10.058 (2012).

724 32 Iwasaki, H., Arai, F., Kubota, Y., Dahl, M. & Suda, T. Endothelial protein C  
725 receptor-expressing hematopoietic stem cells reside in the perisinusoidal  
726 niche in fetal liver. *Blood* **116**, 544-553, doi:10.1182/blood-2009-08-240903  
727 (2010).

728 33 Vento-Tormo, R. *et al.* Single-cell reconstruction of the early maternal-fetal  
729 interface in humans. *Nature* **563**, 347-353, doi:10.1038/s41586-018-0698-6  
730 (2018).

731 34 Efremova, M., Vento-Tormo, M., Teichmann, S. A. & Vento-Tormo, R. CellPhoneDB:  
732 inferring cell-cell communication from combined expression of multi-subunit  
733 ligand-receptor complexes. *Nat Protoc* **15**, 1484-1506, doi:10.1038/s41596-020-  
734 0292-x (2020).

735 35 Li, D. *et al.* VCAM-1(+) macrophages guide the homing of HSPCs to a vascular  
736 niche. *Nature* **564**, 119-124, doi:10.1038/s41586-018-0709-7 (2018).

737 36 Mariani, S. A. *et al.* Pro-inflammatory Aorta-Associated Macrophages Are  
738 Involved in Embryonic Development of Hematopoietic Stem Cells. *Immunity* **50**,  
739 1439-1452 e1435, doi:10.1016/j.immuni.2019.05.003 (2019).

740 37 Vaidya, A. & Kale, V. P. TGF-beta signaling and its role in the regulation  
741 of hematopoietic stem cells. *Syst Synth Biol* **9**, 1-10, doi:10.1007/s11693-015-  
742 9161-2 (2015).

743 38 Ikushima, Y. M. *et al.* Enhanced Angpt1/Tie2 signaling affects the  
744 differentiation and long-term repopulation ability of hematopoietic stem  
745 cells. *Biochem Biophys Res Commun* **430**, 20-25, doi:10.1016/j.bbrc.2012.11.002  
746 (2013).

747 39 Zhang, C. C. & Lodish, H. F. Insulin-like growth factor 2 expressed in a  
748 novel fetal liver cell population is a growth factor for hematopoietic stem  
749 cells. *Blood* **103**, 2513-2521, doi:DOI 10.1182/blood-2003-08-2955 (2004).

750 40 Wong, J. C. *et al.* A glucocorticoid- and diet-responsive pathway toggles  
751 adipocyte precursor cell activity in vivo. *Sci Signal* **9**, ra103,  
752 doi:10.1126/scisignal.aag0487 (2016).

753 41 Caselli, A. *et al.* IGF-1-mediated osteoblastic niche expansion enhances long-  
754 term hematopoietic stem cell engraftment after murine bone marrow  
755 transplantation. *Stem Cells* **31**, 2193-2204, doi:10.1002/stem.1463 (2013).

756 42 Gealekman, O. *et al.* Enhanced angiogenesis in obesity and in response to  
757 PPARgamma activators through adipocyte VEGF and ANGPTL4 production. *Am J*  
758 *Physiol Endocrinol Metab* **295**, E1056-1064, doi:10.1152/ajpendo.90345.2008  
759 (2008).

760 43 Imai, A. *et al.* Adrenomedullin Suppresses Vascular Endothelial Growth Factor-  
761 Induced Vascular Hyperpermeability and Inflammation in Retinopathy. *Am J*  
762 *Pathol* **187**, 999-1015, doi:10.1016/j.ajpath.2017.01.014 (2017).

763 44 Broxmeyer, H. E., Capitano, M., Campbell, T. B., Hangoc, G. & Cooper, S.  
764 Modulation of Hematopoietic Chemokine Effects In Vitro and In Vivo by DPP-  
765 4/CD26. *Stem Cells Dev* **25**, 575-585, doi:10.1089/scd.2016.0026 (2016).

766 45 Macedo, D. B. & Kaiser, U. B. DLK1, Notch Signaling and the Timing of Puberty.  
767 *Semin Reprod Med* **37**, 174-181, doi:10.1055/s-0039-3400963 (2019).

768 46 Fawkner-Corbett, D. *et al.* Spatiotemporal analysis of human intestinal  
769 development at single-cell resolution. *Cell* **184**, 810–826 e823,  
770 doi:10.1016/j.cell.2020.12.016 (2021).

771 47 Asp, M. *et al.* A Spatiotemporal Organ-Wide Gene Expression and Cell Atlas of  
772 the Developing Human Heart. *Cell* **179**, 1647–1660 e1619,  
773 doi:10.1016/j.cell.2019.11.025 (2019).

774 48 Chen, A. *et al.* Large field of view-spatially resolved transcriptomics at  
775 nanoscale resolution. *bioRxiv* (2021).

776 49 Ren, X. *et al.* Reconstruction of cell spatial organization from single-cell  
777 RNA sequencing data based on ligand-receptor mediated self-assembly. *Cell Res*  
778 **30**, 763–778, doi:10.1038/s41422-020-0353-2 (2020).

779 50 Tamplin, O. J. *et al.* Hematopoietic stem cell arrival triggers dynamic  
780 remodeling of the perivascular niche. *Cell* **160**, 241–252,  
781 doi:10.1016/j.cell.2014.12.032 (2015).

782 51 Varol, C., Mildner, A. & Jung, S. Macrophages: development and tissue  
783 specialization. *Annu Rev Immunol* **33**, 643–675, doi:10.1146/annurev-immunol-  
784 032414-112220 (2015).

785 52 Yahara, Y. *et al.* Erythromyeloid progenitors give rise to a population of  
786 osteoclasts that contribute to bone homeostasis and repair. *Nat Cell Biol* **22**,  
787 49–59, doi:10.1038/s41556-019-0437-8 (2020).

788 53 Hoeffel, G. *et al.* C-Myb(+) erythro-myeloid progenitor-derived fetal  
789 monocytes give rise to adult tissue-resident macrophages. *Immunity* **42**, 665–  
790 678, doi:10.1016/j.immuni.2015.03.011 (2015).

791 54 Mass, E. *et al.* Specification of tissue-resident macrophages during  
792 organogenesis. *Science* **353**, doi:10.1126/science.aaf4238 (2016).

793 55 Xue, Y. Y. *et al.* The Vascular Niche Regulates Hematopoietic Stem and  
794 Progenitor Cell Lodgment and Expansion via *klf6a-ccl25b*. *Dev Cell* **42**, 349–+,  
795 doi:10.1016/j.devcel.2017.07.012 (2017).

796 56 Gomez Perdiguero, E. *et al.* Tissue-resident macrophages originate from yolk-  
797 sac-derived erythro-myeloid progenitors. *Nature* **518**, 547–551,  
798 doi:10.1038/nature13989 (2015).

799 57 Ozgur, E., Heidenreich, A., Dagtekin, O., Engelmann, U. & Bloch, W.  
800 Distribution of EphB4 and EphrinB2 in normal and malignant urogenital tissue.  
801 *Urol Oncol* **29**, 78–84, doi:10.1016/j.urolonc.2008.12.020 (2011).

802 58 Allard, J. B. & Duan, C. IGF-Binding Proteins: Why Do They Exist and Why Are  
803 There So Many? *Front Endocrinol (Lausanne)* **9**, 117,  
804 doi:10.3389/fendo.2018.00117 (2018).

805 59 Bach, L. A. IGF-binding proteins. *J Mol Endocrinol* **61**, T11–T28,  
806 doi:10.1530/JME-17-0254 (2018).

807 60 Doulatov, S., Notta, F., Laurenti, E. & Dick, J. E. Hematopoiesis: a human  
808 perspective. *Cell Stem Cell* **10**, 120–136, doi:10.1016/j.stem.2012.01.006  
809 (2012).

810 61 Milyavsky, M. *et al.* A distinctive DNA damage response in human hematopoietic  
811 stem cells reveals an apoptosis-independent role for p53 in self-renewal.

812 *Cell Stem Cell* **7**, 186–197, doi:10.1016/j.stem.2010.05.016 (2010).

813 62 Mohrin, M. *et al.* Hematopoietic stem cell quiescence promotes error-prone DNA  
814 repair and mutagenesis. *Cell Stem Cell* **7**, 174–185,  
815 doi:10.1016/j.stem.2010.06.014 (2010).

816 63 Zhou, F. *et al.* Tracing haematopoietic stem cell formation at single-cell  
817 resolution. *Nature* **533**, 487–492, doi:10.1038/nature17997 (2016).

818 64 Chou, S. & Lodish, H. F. Fetal liver hepatic progenitors are supportive  
819 stromal cells for hematopoietic stem cells. *P Natl Acad Sci USA* **107**, 7799–  
820 7804, doi:10.1073/pnas.1003586107 (2010).

821 65 Zhang, C. C. *et al.* Angiopoietin-like proteins stimulate ex vivo expansion  
822 of hematopoietic stem cells. *Nat Med* **12**, 240–245, doi:10.1038/nm1342 (2006).

823 66 Liu, C. *et al.* Macrophages Mediate the Repair of Brain Vascular Rupture  
824 through Direct Physical Adhesion and Mechanical Traction. *Immunity* **44**, 1162–  
825 1176, doi:10.1016/j.immuni.2016.03.008 (2016).

826 67 Lim, H. Y. *et al.* Hyaluronan Receptor LYVE-1-Expressing Macrophages Maintain  
827 Arterial Tone through Hyaluronan-Mediated Regulation of Smooth Muscle Cell  
828 Collagen. *Immunity* **49**, 326–341 e327, doi:10.1016/j.immuni.2018.06.008 (2018).

829 68 Liang, Q., Su, L., Zhang, D. & Jiao, J. CD93 negatively regulates astrogenesis  
830 in response to MMRN2 through the transcriptional repressor ZFP503 in the  
831 developing brain. *Proc Natl Acad Sci U S A* **117**, 9413–9422,  
832 doi:10.1073/pnas.1922713117 (2020).

833 69 Wang, X. *et al.* Comparative analysis of cell lineage differentiation during  
834 hepatogenesis in humans and mice at the single-cell transcriptome level. *Cell*  
835 *Res* **30**, 1109–1126, doi:10.1038/s41422-020-0378-6 (2020).

836 70 Ding, N. *et al.* Global transcriptome analysis for identification of  
837 interactions between coding and noncoding RNAs during human erythroid  
838 differentiation. *Front Med* **10**, 297–310, doi:10.1007/s11684-016-0452-0 (2016).

839 71 Ren, Y. *et al.* The dynamic interactive network of long non-coding RNAs and  
840 chromatin accessibility facilitates erythroid differentiation. *bioRxiv* (2021).

841 72 Lv, J., Wang, L., Gao, Y., Ding, Y. Q. & Liu, F. 5-hydroxytryptamine  
842 synthesized in the aorta-gonad-mesonephros regulates hematopoietic stem and  
843 progenitor cell survival. *J Exp Med* **214**, 529–545, doi:10.1084/jem.20150906  
844 (2017).

845 73 Oberlin, E. *et al.* VE-cadherin expression allows identification of a new  
846 class of hematopoietic stem cells within human embryonic liver. *Blood* **116**,  
847 4444–4455, doi:10.1182/blood-2010-03-272625 (2010).

848 74 Chen, Y., Haviernik, P., Bunting, K. D. & Yang, Y. C. Cited2 is required for  
849 normal hematopoiesis in the murine fetal liver. *Blood* **110**, 2889–2898,  
850 doi:10.1182/blood-2007-01-066316 (2007).

851 75 Lancini, C., Gargiulo, G., van den Berk, P. C. & Citterio, E. Quantitative  
852 analysis by next generation sequencing of hematopoietic stem and progenitor  
853 cells (LSK) and of splenic B cells transcriptomes from wild-type and *Usp3*-  
854 knockout mice. *Data Brief* **6**, 556–561, doi:10.1016/j.dib.2015.12.049 (2016).

855 76 Zhao, Y. *et al.* ATF4 plays a pivotal role in the development of functional

856 hematopoietic stem cells in mouse fetal liver. *Blood* **126**, 2383-2391,  
857 doi:10.1182/blood-2015-03-633354 (2015).  
858 77 Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R package for  
859 comparing biological themes among gene clusters. *OMICS* **16**, 284-287,  
860 doi:10.1089/omi.2011.0118 (2012).  
861

862 **Figure Legends**

863 **Fig 1. Single-cell transcriptomics atlas of the developing mouse FL.** **a** Schematic diagram  
864 of the procedures for tissue processing, cell isolation, and scRNA-seq profiling of FL.  
865 HSCs/MPPs, hematopoietic stem cells and multipotent progenitors; ECs, endothelial cells; HCs,  
866 hematopoietic cells; NCs, non-hematopoietic/non-endothelial cells. **b** UMAP visualization of  
867 all single cells colored by cell clusters in the FL. MegE progenitor, megakaryocytic-erythroid  
868 progenitor. **c** Heatmap showing row-scaled expression of the top 20 differentially expressed  
869 genes (DEGs, Bonferroni-corrected  $P$ -values  $< 0.05$ , Wilcoxon Rank Sum test) per cluster. **d**  
870 Enriched gene ontology (GO) terms in HSCs/MPPs during FL development. **e** Dot plots of the  
871 enriched DEGs in HSCs/MPPs during FL development.

872

873 **Fig 2. CD93-enriched HSCs/MPPs exhibit enhanced stem cell properties.** **a** GO analysis  
874 among the three HSC/MPP subtypes. **b** Dot plots of the enriched DEGs in the three HSC/MPP  
875 subtypes. **c** Scatter plots of all gene expression in HSC/MPP1 versus HSC/MPP2 (Left) or  
876 versus HSC/MPP2 (Right). Differentially expressed transcription factors are colored. **d**  
877 Boxplots showing the hscScore distribution in the three HSC/MPP subtypes. Student's  $t$  test. **e**  
878 Trajectory analysis by PHATE reconstructing the lineage differentiation from HSCs/MPPs to  
879 lymphoid, and myeloid progenitors, respectively. **f** Heatmap showing the expression pattern of  
880 HSC/MPP signature genes and *Cd93* in the three HSC/MPP subtypes. **g** Donor-derived  
881 chimerism in the peripheral blood (PB) of recipients at 8 weeks after primary transplantation  
882 using CD93<sup>+</sup>SLAM-LSK (CD93<sup>+</sup>HSC) and CD93<sup>-</sup>HSC.  $n = 3$  biological replicates. **h** Donor-  
883 derived chimerism in the PB of recipients at 20 weeks after primary transplantation using

884 CD93<sup>+</sup>HSC and CD93<sup>-</sup>HSC. n = 3 biological replicates. **i** Donor-derived chimerism in the PB  
885 of recipients at 8 weeks after secondary transplantation using CD93<sup>+</sup>HSC and CD93<sup>-</sup>HSC. n =  
886 3 biological replicates. **j** Donor-derived chimerism in the PB of recipients at 16 weeks after  
887 secondary transplantation using CD93<sup>+</sup>HSC and CD93<sup>-</sup>HSC. n = 3 biological replicates. The  
888 statistical results are presented as mean ± SEM. Student's t test: \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ .

889

890 **Fig 3. Integration of scRNA-seq and ST decodes cell-cell interactions between**  
891 **HSCs/MPPs and niche cells. a** Schematic diagram indicating the cell-cell interaction between  
892 HSCs/MPPs and niche cells (Endothelial cells, Stromal cells, Hepatoblasts and Macrophages).  
893 **b** CellPhoneDB analysis showing the major HSC/MPP–niche cell interaction pairs. The  
894 asterisks mean  $P$ -value  $< 0.05$  (permutation test) in corresponding cells. EC, endothelial cell,  
895 Hep, hepatoblast; SC, stromal cell; Mac, macrophage. **c** Dot plots of the ligand (top) and  
896 corresponding receptor (bottom) expression pattern of the major HSC/MPP–niche cell  
897 interaction pairs. **d** Schematic diagram of the procedures for 10x Visium Spatial  
898 Transcriptomics (ST) experiments. **e** Hematoxylin and eosin (HE) staining of embryonic days  
899 (E)14.5 embryo tissue sections (top) included in ST analysis. Sections are shown in the dorsal  
900 (Slice 1) to the ventral direction (Slice 4); Tissue sections (middle) and UMAP visualization  
901 (bottom) showing unbiased clustering of ST spots. **f** Expression pattern of hepatoblast marker  
902 *Afp* in tissue sections. **g** Heatmap showing predicted enrichment scores of spots and two spot  
903 patterns of FL. **h** Spatial feature plots of the two spot patterns in FL sections.

904

905 **Fig 4. Identification of expansion units of HSCs/MPPs. a** Schematic diagram indicating the

906 intra-spots, inter-spots and others. Intra-spots, HSC/MPP-localized spots; Inter-spots,  
907 HSC/MPP-surrounded spots; Others, other distant spots. **b** Boxplots showing the enrichment  
908 score of niche cells in intra-spots, inter-spots, and others. **c** Boxplots showing the normalized  
909 (enrichment) score of niche cells in intra-spots. **d** Boxplots showing the normalized (enrichment)  
910 score of niche cells in inter-spots. **e** Co-expression pattern of *Ptn* and *Ptprs* in the FL section. **f**  
911 Spatial feature plots of *Ptn-Ptprs* enriched HSC/MPP expansion units. Spatial feature plots  
912 showing the expression pattern of ligand gene *Ptn* in niche cells-localized spots (top, red spots),  
913 and receptor gene *Ptprs* in HSCs/MPPs-localized spots (top, blue spots). Spatial feature plots  
914 showing the cell types in HSC/MPP expansion units (middle). Schematic diagram indicating  
915 the *Ptn-Ptprs* enriched HSC/MPP expansion units (bottom). **g** Co-expression pattern of *Mdk*  
916 and *Lrp1* in the FL section. **h** Spatial feature plots of the *Mdk-Lrp1* enriched HSC/MPP  
917 expansion units (inter-spots). **i** Spatial feature plots of the *Mdk-Lrp1* enriched HSC/MPP  
918 expansion units (intra-spots).

919

920 **Fig 5. Macrophages promoting HSC/MPP expansion.** **a** Immunofluorescence analysis  
921 showing the expression of F4/80 (representing macrophages) and c-Kit (representing  
922 HSCs/MPPs) in E14.5 FL cryosections. **b** Immunofluorescence analysis showing the  
923 expression of F4/80 (representing macrophages), and Runx1 (representing HSCs/MPPs) in  
924 E14.5 FL cryosections. **c** The proportion of HSCs/MPPs with and without cellular interaction,  
925 respectively (n > 3 biological replicates). **d** Immunofluorescence analysis showing the  
926 expression of F4/80 (representing macrophages), CD150 (representing HSCs/MPPs), Mecom  
927 (representing HSCs/MPPs) and Hlf (representing HSCs/MPPs) in E14.5 FL cryosections. **e**

928 Schematic diagram of the procedures for HSC/MPP co-culture with macrophages. **f** The  
929 number of HSCs/MPPs (LSK cells) derived from macrophage and HSC/MPP co-culture system.  
930 Macrophages were combined with half of F4/80<sup>low</sup> and half of F4/80<sup>high</sup> macrophages. n = 3  
931 biological replicates. **g** The number of HSCs/MPPs (LSK cells) derived from the MDK (50  
932 ng/mL)-supplemented culture of 100 HSCs/MPPs (LSK, Flt3<sup>+</sup>LSK and SLAM-LSK cells). n =  
933 3 biological replicates. **h** Total cellularity in E14.5 FL after Clodronate-liposome and Control-  
934 liposome treatment. Clodronate-liposome, Clodronate-L; Control-liposome, Control-L, n > 3  
935 biological replicates. **i** The proportion of Lineage<sup>-</sup> (Lin<sup>-</sup>) cells in E14.5 FL after Clodronate-  
936 liposome and Control-liposome treatment, n > 3 biological replicates **j** The proportion of LSK  
937 cells in E14.5 FL after Clodronate-liposome and Control-liposome treatment, n > 3 biological  
938 replicates. **k** The proportion of SLAM-LSK cells in E14.5 FL after Clodronate-liposome and  
939 Control-liposome treatment, n > 3 biological replicates. **l** Flow cytometry analysis showing the  
940 proportions of Lin<sup>-</sup>, LSK, SLAM-LSK cells in E14.5 FL after Clodronate-liposome and  
941 Control-liposome treatment. Scale bars, 20 μm. The statistical results are presented as mean ±  
942 SEM. Student's t test: \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ .

943

944 **Fig 6. Structure niche cells promoting HSC/MPP expansion.** **a** Immunofluorescence  
945 analysis showing the expression of Lyve1 (representing sinusoid ECs) and Runx1 (representing  
946 HSCs/MPPs) in E14.5 FL cryosections. Scale bar, 50 μm. **b** Immunofluorescence analysis  
947 showing the expression of Lyve1 (representing sinusoid ECs) and Runx1 (representing  
948 HSCs/MPPs) in E14.5 FL cryosections. Scale bar, 50 μm. **c** Immunofluorescence analysis  
949 showing the expression of c-Kit (representing HSCs/MPPs), Runx1 (representing HSCs/MPPs),






950 and EphrinB2 (representing arterial portal vessels) in E14.5 FL cryosections. Yellow  
951 arrowheads indicate the c-Kit and Runx1 double-positive HSCs/MPPs. Scale bar, 50  $\mu\text{m}$ . **d**  
952 Immunofluorescence analysis showing the expression of c-Kit (representing HSCs/MPPs),  
953 Runx1 (representing HSCs/MPPs), and EphB4 (representing veins) in E14.5 FL cryosections.  
954 Yellow arrowheads indicate the c-Kit and Runx1 double-positive HSCs/MPPs. Scale bar, 25  
955  $\mu\text{m}$ . **e** Dot plots of the expression patterns of *Igfbp1*, *Igfbp5*, and *Igfbp7* in three structural niche  
956 cells (endothelial cell, stromal cell, and hepatoblast). **f** The number of HSCs/MPPs (LSK cells)  
957 derived from the factors (50 ng/mL concentration of each factor)-supplemented culture of 100  
958 SLAM-LSK cells from E14.5 FL. n = 3 biological replicates. **g** The number of HSCs/MPPs  
959 (LSK cells) derived from the factors (50 ng/mL concentration of each factor)-supplemented  
960 culture of 100 Flt3<sup>-</sup>-LSK cells from E14.5 FL. n = 3 biological replicates. **h** The number of  
961 HSCs/MPPs (LSK cells) derived from the factors (50 ng/mL concentration of each factor)-  
962 supplemented culture of 100 LSK cells from E14.5 FL. n = 3 biological replicates. The  
963 statistical results are presented as mean  $\pm$  SEM. Student's t test: \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ .


964

965 **Fig 7. Cross-species analysis of FL hematopoiesis between mice and humans. a** UMAP  
966 visualization of all cell types in the mouse E14.5 FL. Numbers indicate cell types; each dot  
967 represents one cell. **b** UMAP visualization of the FL cell populations from mice (E14.5) and  
968 humans (11 post-conception weeks). Yellow indicates the mouse cell population and blue  
969 indicates the human cell population. **c** GO analysis of the top DEGs related to biological  
970 processes in human HSCs/MPPs. **d** GO analysis of the top DEGs related to biological processes  
971 in mouse HSCs/MPPs. **e** Ligand-receptor interaction network showing the potential


972 communications between human HSCs/MPPs and niche cells. **f** Heatmap showing the major  
973 human HSC/MPP-niche cell interaction pairs. The asterisks mean  $P$ -value  $< 0.05$  (permutation  
974 test) in corresponding cells. **g-h** Immunofluorescence analysis showing the expression of CD68  
975 (representing macrophages) and CD34 (representing HSCs/MPPs) in human 11 post-  
976 conception week FL section. Scale bars, 20  $\mu\text{m}$ . **i** The proportion of HSCs/MPPs with and  
977 without cellular interaction, respectively ( $n > 3$  biological replicates). **j** The number of human  
978 CD34<sup>+</sup>HSCs/MPPs derived from mouse macrophage and HSC/MPP co-culture system. The  
979 statistical data are the cell number of CD34<sup>+</sup> cells (total number of co-culture cells  $\times$  the  
980 proportion of CD34<sup>+</sup> cells in total co-cultured cells) after co-culture. F4/80<sup>low</sup> macrophages were  
981 CD45<sup>+</sup>CD11b<sup>+</sup>F4/80<sup>low</sup> macrophages, F4/80<sup>high</sup> macrophages were CD45<sup>+</sup>CD11b<sup>low</sup>F4/80<sup>high</sup>  
982 macrophages, macrophages were combined with half of F4/80<sup>low</sup> and half of F4/80<sup>high</sup>  
983 macrophages.  $n > 3$  biological replicates. The statistical results are presented as mean  $\pm$  SEM.  
984 Student's t test: \*,  $P < 0.05$ ; \*\*,  $P < 0.01$ ; \*\*\*,  $P < 0.001$ .


985


**Fig. 1****a****b****c****d****e**

**Fig. 2**


**Fig. 3**












**Fig. 4**

**Fig. 5**

**Fig. 6**



**Fig. 7****a****b****c****d****e****f****g****h****i****j**